GT
The startup develops regenerative drugs using differentiated pluripotent stem cells to treat liver diseases, specifically targeting acute and chronic severe liver failure. By formulating frozen allogeneic liver cells, the company provides a therapeutic alternative to organ transplantation, enhancing treatment options for patients.
Updated 18 months ago
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GO
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops regenerative drugs using differentiated pluripotent stem cells to treat liver diseases, specifically targeting acute and chronic severe liver failure. By formulating frozen allogeneic liver cells, the company provides a therapeutic alternative to organ transplantation, enhancing treatment options for patients.